EC
DVAX

EntryPoint Capital’s Dynavax Technologies DVAX Stock Holding History

EntryPoint Capital’s Portfolio DVAX Stock Details DVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-26,094
Closed -$291K – 789
2024
Q3 		$291K Buy
+26,094
New +$288K 0.17% 261

Other funds holding DVAX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EntryPoint Capital's DVAX Position: Q4 2024 in Review

EntryPoint Capital sold out of Dynavax Technologies (DVAX) in Q4 2024, closing a stake of 26,094 shares — an estimated $291K sold.

EntryPoint Capital first reported a position in DVAX in Q3 2024 and held it in 1 quarter. The position peaked at $291K in Q3 2024. 256 funds tracked by Wall St. Rank hold DVAX as of Q4 2024.

  • EntryPoint Capital reported no remaining Dynavax Technologies position as of Q4 2024 after selling out during the quarter.
  • EntryPoint Capital sold 26,094 Dynavax Technologies shares in Q4 2024, an estimated $291K.
  • EntryPoint Capital first reported a position in Dynavax Technologies in Q3 2024 and held it in 1 quarter.
  • EntryPoint Capital's Dynavax Technologies position peaked at $291K in Q3 2024.
  • 256 funds tracked by Wall St. Rank held Dynavax Technologies as of Q4 2024.

Based on EntryPoint Capital's 13F filing for Q4 2024, filed 11 Feb 2025.